MY 0012
Alternative Names: MY-0012Latest Information Update: 12 Sep 2024
Price :
$50 *
At a glance
- Originator Wuhan Createrna Science and Technology
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 29 Aug 2024 Discontinued - Preclinical for Rheumatoid arthritis in China (unspecified route) (Wuhan Createrna Science and Technology pipeline, August 2024)
- 27 Aug 2024 Preclinical trials in Rheumatoid arthritis in China (unspecified route) before August 2024 (Wuhan Createrna Science and Technology pipeline, August 2024)